# EDGAR Filing Document

**Accession Number:** 0001468929
**File Stem:** 0001493152-26-024286
**Filing Date:** 2026-5
**Character Count:** 5695
**Document Hash:** c1f0889aea2e0b91969b26bf42b607c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024286.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001493152-26-024286

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260506

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kieser Brian Joseph
- **CENTRAL INDEX KEY:** 0002133654

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41173
- **FILM NUMBER:** 26995545

**MAIL ADDRESS:**
- **STREET 1:** 29 CHAMPIONS WAY
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78258
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEXGEL, INC.
- **CENTRAL INDEX KEY:** 0001468929
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 264042544
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2150 CABOT BLVD WEST,
- **STREET 2:** SUITE B
- **CITY:** LANGHORNE
- **STATE:** PA
- **ZIP:** 19047
- **BUSINESS PHONE:** 215 702-8550

**MAIL ADDRESS:**
- **STREET 1:** 2150 CABOT BLVD WEST,
- **STREET 2:** SUITE B
- **CITY:** LANGHORNE
- **STATE:** PA
- **ZIP:** 19047

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AquaMed Technologies, Inc.
- **DATE OF NAME CHANGE:** 20090723

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kieser Brian Joseph<br><sub>(Last) (First) (Middle)</sub><br>C/O NEXGEL, INC.<br>2150 CABOT BOULEVARD, WEST, SUITE B<br><sub>(Street)</sub><br>LANGHORNE, PA 19047<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>NEXGEL, INC. [ NXGL ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-05-06 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Convertible Promissory Note (right to buy) (the "Note")<sup>(1)</sup> | 2026-04-17 | 2027-10-17 | Common Stock | 9166667 | $0.60 | I | By Sequence LifeScience, Inc.<sup>(2)</sup> |
| Warrant (right to buy) (the "Warrant")<sup>(1)</sup> | 2026-04-17 | 2031-04-17 | Common Stock | 4583334 | $0.80 | I | By Sequence LifeScience, Inc.<sup>(2)</sup> |

---

### Footnotes:

(1) The Note is convertible into shares of the Issuer's common stock (the "Common Stock"), and the Warrant is exercisable for shares of Common Stock, at any time at the option of the holder, subject to (i) a beneficial-ownership limitation that prevents conversion or exercise to the extent the holder, together with its affiliates, would beneficially own more than 4.99% of the outstanding shares of Common Stock after such conversion or exercise, and (ii) certain other limitations set forth in the Note and Warrant. The Warrant was issued to the Reporting Person in connection with, and as part of the consideration for, the purchase of the Note, for no additional consideration beyond the Note purchase price.

(2) The securities are held of record by Sequence LifeScience, Inc. ("Sequence"). The Reporting Person is the indirect sole owner of Sequence and may be deemed to have voting and investment power over the securities held by Sequence. The Reporting Person disclaims beneficial ownership of the securities held by Sequence except to the extent of his pecuniary interest therein.

**Signature:** /s/ Brian J. Kieser  
**Date:** 2026-05-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**